Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide),

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.

A new study is out that compares the effectiveness of two popular weight loss drugs, Wegovy and Zepbound. The study, which was conducted by Eli Lilly, the maker of Zepbound, found that weight loss with Zepbound was significantly more than Wegovy.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.

Cannabis might help with weight loss by targeting the endocannabinoid system, potentially suppressing appetite, boosting metabolism, and offering new, less invasive treatments for obesity and

With so many weight loss medications on the market, it’s easy to feel overwhelmed by the options. From brand-name heavy hitters to compounded varieties, each promises to help shed pounds. But a recent head-to-head trial comparing Zepbound vs.